Broad-Spectrum Antibiotics Ineffective as Initial Pneumonia Treatment
|
By HospiMedica International staff writers Posted on 09 Mar 2020 |
A new study shows that hospitalized pneumonia patients prescribed antibiotics that target methicillin-resistant Staphylococcus aureus (MRSA) fare no better than standard medical care.
Researchers at the Veterans Affairs Salt Lake City Health Care System (UT, USA) and the University of Utah (UU; Salt Lake City, USA) conducted a retrospective cohort study involving 88,605 hospitalized patients (median age 70 years, predominantly men) who received either anti-MRSA or standard therapy for community-onset pneumonia. The main outcomes were 30-day all-cause mortality, after adjustment for patient comorbidities, vital signs, and laboratory results. Secondary outcomes included kidney injury and secondary infections with Clostridioides difficile, vancomycin-resistant Enterococcus species, or gram-negative bacilli.
The results revealed no discernable benefit of anti-MRSA treatment in addition to standard treatment. In fact, anti-MRSA treatment was associated with a 40 % higher risk of dying within 30 days of discharge, perhaps due to potentially severe side effects of vancomycin, including increased incidence of kidney failure and secondary infections. The researchers also observed that as doctors became more aware of MRSA infection in the lungs, they tended to use anti-MRSA drugs as initial treatment, despite the fact that MRSA only accounts for about 2% of pneumonia cases. The study was published on February 17, 2020, in JAMA Internal Medicine.
“In the absence of better tests to identify MRSA as a potential pathogen causing the disease, using anti-MRSA therapies does not seem to offer any advantage over standard treatment therapy,” said lead author Barbara Ellen Jones, MD, MSc, of UU. “Under these circumstances, it may be safer for patients if physicians to stick to standard antibiotic treatments for a couple of days to see how patients are doing, rather than leaping into anti-MRSA therapy right off the bat.”
Pneumonia is the eighth leading cause of death in the United States, accounting for more than one million hospitalizations and about 50,000 deaths each year. It can be caused by viruses, fungi, and bacteria, including MRSA.
Related Links:
Veterans Affairs Salt Lake City Health Care System
University of Utah
Researchers at the Veterans Affairs Salt Lake City Health Care System (UT, USA) and the University of Utah (UU; Salt Lake City, USA) conducted a retrospective cohort study involving 88,605 hospitalized patients (median age 70 years, predominantly men) who received either anti-MRSA or standard therapy for community-onset pneumonia. The main outcomes were 30-day all-cause mortality, after adjustment for patient comorbidities, vital signs, and laboratory results. Secondary outcomes included kidney injury and secondary infections with Clostridioides difficile, vancomycin-resistant Enterococcus species, or gram-negative bacilli.
The results revealed no discernable benefit of anti-MRSA treatment in addition to standard treatment. In fact, anti-MRSA treatment was associated with a 40 % higher risk of dying within 30 days of discharge, perhaps due to potentially severe side effects of vancomycin, including increased incidence of kidney failure and secondary infections. The researchers also observed that as doctors became more aware of MRSA infection in the lungs, they tended to use anti-MRSA drugs as initial treatment, despite the fact that MRSA only accounts for about 2% of pneumonia cases. The study was published on February 17, 2020, in JAMA Internal Medicine.
“In the absence of better tests to identify MRSA as a potential pathogen causing the disease, using anti-MRSA therapies does not seem to offer any advantage over standard treatment therapy,” said lead author Barbara Ellen Jones, MD, MSc, of UU. “Under these circumstances, it may be safer for patients if physicians to stick to standard antibiotic treatments for a couple of days to see how patients are doing, rather than leaping into anti-MRSA therapy right off the bat.”
Pneumonia is the eighth leading cause of death in the United States, accounting for more than one million hospitalizations and about 50,000 deaths each year. It can be caused by viruses, fungi, and bacteria, including MRSA.
Related Links:
Veterans Affairs Salt Lake City Health Care System
University of Utah
Latest Critical Care News
- Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreSurgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







